XBIO
Xenetic Biosciences, Inc.2.0700
-0.2700-11.5%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
4.74MP/E (TTM)
-Basic EPS (TTM)
-2.04Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
Q2 results and DNase advances
Xenetic Biosciences expanded its partnership with The Scripps Research Institute to push forward proof-of-concept studies on systemic DNase I combined with CAR T-cell therapies, while PeriNess kicked off patient dosing in a pancreatic cancer trial blending DNase I with FOLFIRINOX. The company posted a $0.7 million net loss for Q2 2025, down from prior year thanks to lower R&D and G&A costs after executive separations. Cash stood at $4.8 million. Progress builds toward an IND filing.
10-Q
Q2 FY2025 results
Xenetic Biosciences posted royalty revenue of $589,897 for Q2 FY2025 ended June 30, 2025, down 18.8% y/y from $726,404 yet up sequentially from Q1's $593,261 (derived). Operating expenses fell sharply, trimming the net loss to $688,703 from $1.3 million y/y—a 45.9% improvement—thanks to lower R&D and G&A outlays after prior-year executive severances. YTD revenue held steady at $1.2 million, with net loss narrowing 35.5% to $1.6 million versus 2024, while diluted EPS of $(1.03) aligns with 1,542,139 weighted shares. Cash burned $1.4 million in operations, leaving $4.8 million on hand with no debt; free cash flow not disclosed in the 10-Q. Exploratory DNase studies advanced via Scripps and UVA pacts. Geopolitical tensions pose ongoing supply risks.
8-K
Q1 loss narrows to $0.9M
Xenetic Biosciences reported a narrowed Q1 2025 net loss of $0.9 million, with revenue up 16.1% to $0.6 million and operating expenses down 13.7% to $1.5 million, thanks to reduced personnel costs after executive departures. Cash stood at $5.2 million, supporting DNase I program advances toward IND for pancreatic carcinoma treatment. PeriNess inked a Clinical Study Agreement for osteosarcoma and Ewing sarcoma studies. Progress builds on preclinical data, yet funding remains a key risk.
CBIO
Crescent Biopharma, Inc.
12.92-0.29
ETNB
89bio, Inc.
14.84+0.00
IMA
ImageneBio, Inc.
6.25+0.08
INMB
INmune Bio Inc.
1.89-0.02
PHIO
Phio Pharmaceuticals Corp.
1.08-0.01
RGBP
Regen Biopharma, Inc.
0.01-0.00
XBIT
XBiotech Inc.
2.45-0.08
XENE
Xenon Pharmaceuticals Inc.
43.00-0.60
XNCR
Xencor, Inc.
16.55-0.24
ZBIO
Zenas BioPharma, Inc.
36.89+4.30